The 15-year investigation, by researchers from the University of Glasgow, has shown that patients treated with statins for five years suffer 27 per cent fewer non-fatal heart attacks or deaths due to heart disease.
It appears that the statin treatment reduces the rate occurrence of heart disease events, even after patients stop taking the drug.
Professor Ian Ford, who led the study, said: “We believe that this remarkable ongoing benefit is due to a stabilizing of existing disease in the coronary arteries and significant slowing of further progression of disease. This benefit appears to have persisted for 10 years and may have conferred a lifelong advantage on those treated with the statin.”
The results are published in the New England Journal of Medicine.
The investigation was carried out by the same team who produced the landmark 1995 study that opened the door worldwide for patients to be treated with a statin.
The West of Scotland Coronary Prevention Study followed volunteers over a 15-year period to investigate the treatment benefits and assess the long-term safety of statin use.
The first results of the study, published in 1995, showed that the risk of death from coronary heart disease or non-fatal heart attack was reduced significantly in men who were prescribed a statin for five years.
A total of 6595 Scottish middle-aged men, who had high cholesterol levels but who had not previously suffered a heart attack, were used in the study. One half of the group were prescribed a statin, while the others were given a placebo.
These patients have now been followed for 15 years and provided the basis for the latest findings.
Professor Ford said: “The results of the follow-up provide strong support for the safety of five years of statin use.
“When fatal and non-fatal heart disease events were studied, it was found that, despite the fact that most of the participants were not treated with a statin after the first five years of the trial there was evidence of the group originally receiving the statin continuing to be at lower risk of having a heart disease event.
“In fact, remarkably, five years of treatment with a statin resulted in 27 per cent fewer non-fatal heart attacks or deaths due to heart disease over the period of 15 years. There was a significant 12 per cent reduction in deaths over the entire period, with deaths due to heart disease reduced by 22 per cent.
“This suggests that statin treatment has a long-term beneficial effect in slowing the development of coronary artery disease.”
Professor Stuart Cobbe, lead cardiologist in the study, said: “We were very surprised to find that patients who had been treated for 5 years with a statin continued to have significantly fewer heart attacks and other coronary events compared to those treated with a placebo treatment. This benefit appeared to extend at least 10 years after the original trial.
“These results are very reassuring for patients who might be concerned about safety when taking a drug for a very long period of time. There was no evidence of adverse health problems associated with taking a statin for 5 years.
“Importantly, the relative risk reduction in the 10 years after the trial was lower than that observed during the trial, suggesting that there is still additional benefit from continuing to take statin treatment beyond 5 years. The researchers emphasize therefore that this research does not suggest that patients should stop taking their treatment after five years.
Professor Chris Packard, an expert on cholesterol lowering drugs, said: “The impact of statin treatment appeared to persist long after the active phase of the trial. This suggests that the drugs have lasting beneficial effects on the artery wall possibly by stabilising plaques that might be about to rupture and cause a heart attack.
“What is also important to note is that we made use of the electronic records that Scotland has held for hospital admissions, cancer registrations and deaths since the early 1980s. This study, based on following up participants’ electronic medical records, demonstrates the significant benefits that such records can provide for medical researchers. This Scottish resource is unique in the UK and is equalled in very few places worldwide.”
The research was supported by a research grant from the Chief Scientist Office, Scotland.
Martin Shannon | alfa
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
Researchers from the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science, the Italian Space Agency (ASI), and the Instituto Geofisico--Escuela Politecnica Nacional (IGEPN) of Ecuador, showed an increasing volcanic danger on Cotopaxi in Ecuador using a powerful technique known as Interferometric Synthetic Aperture Radar (InSAR).
The Andes region in which Cotopaxi volcano is located is known to contain some of the world's most serious volcanic hazard. A mid- to large-size eruption has...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
16.08.2017 | Physics and Astronomy
16.08.2017 | Materials Sciences
16.08.2017 | Interdisciplinary Research